Sunday, July 12, 2020

Cytomegalovirus Disease Prevention in High-Risk Liver Transplant Patients: Preemptive Therapy or Prophylaxis?

Transplant News Sharing // News from Source

Cytomegalovirus Disease Prevention in High-Risk Liver Transplant Patients: Preemptive Therapy or Prophylaxis?

Cytomegalovirus (CMV) is a common pathogen post-transplant. CMV-seronegative patients lack personal immunity. If they receive organ transplants from seropositive donors, the risk for infection from the transplanted organ is high. Antiviral prophylaxis with valganciclovir for at least 3 months is the current gold standard for prevention of CMV infections post liver transplant.

An alternative method is preemptive therapy: starting antivirals once surveillance testing detects early asymptomatic CMV viremia. Now, a study suggests using preemptive therapy may lower the incidence of CMV disease over 12 months compared with antiviral prophylaxis in this high-risk population.

A research team from Pittsburgh randomized 205 CMV seronegative liver transplant patients who received grafts from CMV seropositive donors in a prospective multicenter trial in 6 US transplant centers. The study’s 2 arms compared prophylaxis with preemptive therapy 1:1. The primary outcome measure was the incidence of CMV disease by 12 months post-transplant.

These researchers monitored patients in the preemptive therapy arm with weekly testing for CMV viremia for 100 days. If they detected any level of viremia, they started valganciclovir 900 mg by mouth twice daily until the patient had 2 consecutive negative PCR tests 1 week apart.

The patients in the comparator arm received antiviral prophylaxis with valganciclovir 900 mg daily for 100 days after transplant, with no monitoring.

The incidence of CMV disease at 12 months was significantly lower in patients who received preemptive therapy (9%) than in the antiviral prophylaxis arm (19%).

Preemptive therapy in liver transplant recipients at high-risk for contracting CMV may be a viable approach. Clinicians cannot extrapolate these results to other types of organ transplants due to biologic differences and differences in the intensity of immunosuppressive therapies.

Additionally, preemptive therapy requires weekly monitoring and timely initiation of antiviral therapy. Some transplant programs may be unable to provide these components.

The authors acknowledge that further research is needed to replicate their findings and assess long-term outcomes.

Singh N, Winston DJ, Razonable RR, et al. Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020;323(14):1378–1387. doi:10.1001/jama.2020.3138

About the Author
Samantha Troy is a 2021 PharmD Candidate at the University of Connecticut.

Transplant News Sharing // “Liver Transplants” – Google News from Source

Transplant News
Transplant News
Transplant News brings you original and carefully curated aggregate news stories, articles and content that matter to the transplant community, from top publishers around the web. Everything from patient stories, to the latest in transplant innovation, TN is your window into the world of transplantation.

Facebook Comments


Must Read

Is tandem transplant appropriate for patients with high-risk neuroblastoma?

Transplant News Sharing // News from Source ...

A Stem Cell Transplant Has Cured Two HIV Patients – Now. Powered by Northrop Grumman

Transplant News Sharing // News from Source Human immunodeficiency virus (HIV) has been traced as far back as a century ago, but it wasn’t...

Young mother in “desperate” need of kidney transplant

Transplant News Sharing // News from Source WAUSAU, Wis. (WSAW) - There are nearly 114,000 people on the national waiting list for organ transplants...

Wakefield bride-to-be born suffering from cancer needs second life-saving liver transplant before marrying fiance

Transplant News Sharing // News from Source Rebecca Gough and James Towse.Rebecca Gough - who said she needs a full transplant within 12-months...

Not just COVID-19, shortness of breath could be a symptom of heart failure

Transplant News Sharing // News from Source ...